Sindings from the latest large randomized controlled study do not support use of even a single prostate-specific antigen (PSA) test for prostate cancer screening. The U.K. study, published March 6 in the Journal of the American Medical Association showed that while the single test screening intervention does detect more prostate cancer cases compared to no screening, testing had no significant effect on prostate cancer mortality after a median followup of 10 years. Shared Decision Making Not Taking Hold for PSA Testing Researchers from the American Cancer Society (Atlanta, Ga.) retrospectively analyzed data from 9,598 men aged 50 years and older participating in the 2010 and 2015 National Health Interview Survey in order to assess changes in shared decision making for PSA testing. In 2017, the U.S. Preventive Service Task Force released updated recommendations, stating that clinicians should inform men (aged 55 to 69 years) about the potential benefits and harms of PSA testing, so that the decision to undergo testing is an individual one. The researchers found that a similar proportion (about 60 percent) of men with recent PSA testing reported at least one shared decision-making element in 2010 and 2015. However, over the study period, there was a slight […]